CSIMarket
 
Perspective Therapeutics Inc   (CATX)
Other Ticker:  
 
 
Price: $1.2400 $-0.02 -1.587%
Day's High: $1.2791 Week Perf: 3.33 %
Day's Low: $ 1.23 30 Day Perf: 37.78 %
Volume (M): 1,988 52 Wk High: $ 1.36
Volume (M$): $ 2,465 52 Wk Avg: $0.53
Open: $1.26 52 Wk Low: $0.21



 Market Capitalization (Millions $) 348
 Shares Outstanding (Millions) 281
 Employees -
 Revenues (TTM) (Millions $) 8
 Net Income (TTM) (Millions $) -26
 Cash Flow (TTM) (Millions $) -40
 Capital Exp. (TTM) (Millions $) 1

Perspective Therapeutics Inc
Perspective Therapeutics Inc is a biotech company that focuses on developing innovative therapies for various diseases and medical conditions. The company's goal is to provide groundbreaking solutions that improve patient outcomes and quality of life.

They specialize in developing therapeutics that target specific biological pathways and mechanisms to address the underlying causes of diseases. The company's research and development efforts encompass a wide range of therapeutic areas, including oncology, neurology, immunology, and rare genetic disorders.

Perspective Therapeutics Inc utilizes advanced technologies and scientific approaches to identify and develop small molecule drugs, biologics, and gene therapies. The company collaborates with leading academic institutions, research organizations, and pharmaceutical companies to leverage their collective expertise and resources.

Their team consists of experienced scientists, researchers, and clinicians who are dedicated to translating scientific discoveries into clinically relevant treatment options. The company's approach is rooted in rigorous scientific research, preclinical studies, and clinical trials to ensure the safety and efficacy of their therapeutic candidates.

Perspective Therapeutics Inc aims to make a significant impact on the healthcare industry by introducing new and effective treatment options for patients worldwide. Ultimately, their mission is to improve the lives of individuals affected by challenging diseases through innovative therapies that address unmet medical needs.


   Company Address: 350 Hills St., Suite 106 Richland 99354 WA
   Company Phone Number: 375-1202   Stock Exchange / Ticker: NYSE CATX
   CATX is expected to report next financial results on May 14, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Announcement

Perspective Therapeutics Secures $87.4 Million in Private Placement to Drive Innovative Cancer Treatments

Published Mon, Mar 4 2024 2:45 PM UTC

In a significant development, Perspective Therapeutics, a pioneering radiopharmaceutical company, announced an investment agreement with a group of institutional accredited investors. The company aims to raise approximately $87.4 million through a private placement, with the proceeds dedicated to advancing their advanced treatment applications for cancers across the body. Th...

Announcement

Perspective Therapeutics Scores Financial Triumph with $69.0 Million Public Offering and $20.8 Million Private Placement, Fuelling the Fight Against Cancer

Published Mon, Jan 22 2024 9:05 PM UTC

Operating under its company label on the NYSE American as CATX, Perspective Therapeutics confidently strides on its quest to innovate and revolutionize the realm of cancer therapeutics through its adept usage of medical isotopes. These often overlooked miracles of modern medical science provide an opportunity for significant advancements in the targeted delivery of radiation...

Perspective Therapeutics Inc

Perspective Therapeutics Inc Regains Strong Financial Footing in Q1 2023, While Revenue Moderately Retreats

According to the latest financial news, Perspective Therapeutics Inc has achieved a significant improvement in its financial performance in the first quarter of 2023. The company has reported a balanced book of $0.00 per share, which is a substantial growth compared to the previous year's $-0.01 per share, and the previous reporting period's $-0.03 per share. This result is a promising sign for the company, indicating its resilience and sustainability among the competition in the market.
However, the company's revenue for the January to March 31, 2023 period has dropped by -26.74% to $2.06 million from the same period a year ago, where it had been $2.82 million. Despite the decline in revenue, the company's sequential revenue growth has improved by 20.151% from the previous reporting period's $1.72 million. This indicates that the company has been able to overcome the challenges it faced in the past year and is now on the path to recovery.






 

Perspective Therapeutics Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com